All In Biotech

Drug Trial Radar · NCT05417087

Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg and 'Trintellix' (Vortioxetine) Tablets 20 mg in Healthy Adult Human Subjects Under Fasting Conditions

Last checked: Nov 20, 2026Latest source record: Apr 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jun 27, 2022

Primary completion

Sep 2, 2022

Study completion Sep 2, 2022

Sponsor

Sponsor type
Industry
First posted
Jun 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 25 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open label, randomized, three-period, three-treatment \[Treatment A (test product administered without water), Treatment B (test product administered with water) and Treatment C (Reference product administered with water)\], six-sequence, crossover, balanced, single dose oral bioequivalence study.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

  • Vortioxetine Hemihydrobromide Orally Disintegrating TabletsDrug

    Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine

  • Vortioxetine Hydrobromide TabletsDrug

    Vortioxetine Hydrobromide Tablets 20mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma samples will be tested. PK parameter Cmax will be reported. Ratios of PK parameters on SF001 ODT and Trintellix fall within 80.00% to 125.00%Time frame: In each period, total 28 blood samples will be collected at pre-dose (0.0 hour) and until 240 hours post dose
  2. Plasma samples will be tested. PK parameter AUCi will be reported. Ratios of PK parameters on SF001 ODT and Trintellix fall within 80.00% to 125.00%Time frame: In each period, total 28 blood samples will be collected at pre-dose (0.0 hour) and until 240 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cliantha Research Limited

    Ahmedabad, Gujarat, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.